Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) had its price objective lifted by Robert W. Baird from $514.00 to $568.00 in a report released on Monday, Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Robert W. Baird‘s price target indicates a potential upside of 86.19% from the company’s current price.
PRAX has been the topic of a number of other reports. Wall Street Zen lowered shares of Praxis Precision Medicines from a “hold” rating to a “sell” rating in a report on Saturday, October 17th. Wells Fargo & Company lowered their price target on shares of Praxis Precision Medicines from $362.00 to $343.00 and set an “equal weight” rating for the company in a report on Tuesday, November 10th. JPMorgan Chase & Co. assumed coverage on shares of Praxis Precision Medicines in a research note on Friday, October 16th. They set an “overweight” rating and a $700.00 price objective on the stock. Raymond James Financial restated a “strong-buy” rating and set a $945.00 target price on shares of Praxis Precision Medicines in a research report on Monday, August 17th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $826.00 target price on shares of Praxis Precision Medicines in a research note on Monday, November 9th. Three analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $656.42.
Check Out Our Latest Stock Report on Praxis Precision Medicines
Praxis Precision Medicines Price Performance
Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) last posted its earnings results on Monday, November 9th. The company reported ($3.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.54) by $0.31. As a group, research analysts expect that Praxis Precision Medicines will post -13.72 EPS for the current fiscal year.
Institutional Investors Weigh In On Praxis Precision Medicines
Institutional investors have recently bought and sold shares of the stock. Janus Henderson Group PLC increased its position in Praxis Precision Medicines by 6.8% during the first quarter. Janus Henderson Group PLC now owns 3,458,863 shares of the company’s stock worth $1,113,514,000 after purchasing an additional 218,777 shares during the last quarter. Perceptive Advisors LLC raised its stake in Praxis Precision Medicines by 2.0% during the first quarter. Perceptive Advisors LLC now owns 2,035,986 shares of the company’s stock worth $655,974,000 after purchasing an additional 40,000 shares during the period. Bank of America Corp DE raised its stake in Praxis Precision Medicines by 2.3% during the first quarter. Bank of America Corp DE now owns 534,604 shares of the company’s stock worth $172,244,000 after purchasing an additional 11,841 shares during the period. Vivo Capital LLC raised its stake in Praxis Precision Medicines by 3.0% during the first quarter. Vivo Capital LLC now owns 338,895 shares of the company’s stock worth $109,189,000 after purchasing an additional 10,000 shares during the period. Finally, Marshall Wace LLP boosted its holdings in shares of Praxis Precision Medicines by 61.7% in the 3rd quarter. Marshall Wace LLP now owns 221,602 shares of the company’s stock valued at $64,537,000 after purchasing an additional 84,594 shares during the last quarter. 67.84% of the stock is currently owned by hedge funds and other institutional investors.
Praxis Precision Medicines Company Profile
Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing treatments for neurological and psychiatric disorders. The company applies neuroscience and precision-medicine research to conditions involving abnormalities in brain circuits and neuronal activity. Its investigational programs have included small-molecule therapies for disorders such as essential tremor and epilepsy, as well as genetic-medicine approaches for certain rare neurological conditions. These candidates are in development and are not approved treatments.
Further Reading
- Five stocks we like better than Praxis Precision Medicines
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Praxis Precision Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Praxis Precision Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
